{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T23:41:29Z","timestamp":1718235689761},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40261-018-0666-9","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T07:12:27Z","timestamp":1529651547000},"page":"801-811","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Budget Impact Analysis of Oral Fisiogen Ferro Forte\u00ae versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain"],"prefix":"10.1007","volume":"38","author":[{"given":"Josep","family":"Darb\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meritxell","family":"Ascanio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"issue":"1","key":"666_CR1","first-page":"78","volume":"30","author":"A Otero","year":"2010","unstructured":"Otero A, De Francisco A, Gayoso P, Garc\u00eda F. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia. 2010;30(1):78\u201386.","journal-title":"Nefrologia."},{"issue":"3","key":"666_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1523-1755.2004.00880.x","volume":"66","author":"T Fehr","year":"2004","unstructured":"Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004;66(3):1206\u201311.","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"666_CR3","first-page":"1","volume":"19","author":"F Locatelli","year":"2004","unstructured":"Locatelli F, Aljama P, B\u00e1r\u00e1ny P, Canaud B, Carrera F, Eckardt KU, et al. European Best Practice Guidelines Working Group. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Revised. Nephrol Dial Transpl. 2004;19(Suppl 2):1\u201347.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"666_CR4","first-page":"302","volume":"34","author":"M Gorostidi","year":"2014","unstructured":"Gorostidi M, Santamar\u00eda R, Alc\u00e1zar R, Fern\u00e1ndez-Fresnedo G, Galcer\u00e1n JM, Goicoechea M, et al. Documento de la Sociedad Espa\u00f1ola de Nefrolog\u00eda sobre las gu\u00edas KDIGO para la evaluaci\u00f3n y el tratamiento de la enfermedad renal cr\u00f3nica. Nefrolog\u00eda (Madrid). 2014;34(3):302\u201316.","journal-title":"Nefrolog\u00eda (Madrid)."},{"issue":"Suppl 1","key":"666_CR5","first-page":"2217","volume":"130","author":"E Brilli","year":"2017","unstructured":"Brilli E, Lipinski P, Barnadas R, Camacho M, Fabiano A, Giordano G, et al. Sucrosomial iron absorption involve M cells interaction. Blood. 2017;130(Suppl 1):2217.","journal-title":"Blood"},{"key":"666_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ejps.2017.10.021","volume":"111","author":"A Fabiano","year":"2018","unstructured":"Fabiano A, Brilli E, Fogli S, Beconcini D, Carpi S, Tarantino G, et al. Sucrosomial\u00ae iron absorption studied by in vitro and ex vivo models. Eur J Pharm Sci. 2018;111:425\u201331.","journal-title":"Eur J Pharm Sci"},{"issue":"15","key":"666_CR7","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1080\/14767058.2016.1224841","volume":"30","author":"F Parisi","year":"2017","unstructured":"Parisi F, Berti C, Mand\u00f2 C, Martinelli A, Mazzali C, Cetin I. Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: a randomized control trial. J Matern Fetal Neonatal Med. 2017;30(15):1787\u201392.","journal-title":"J Matern Fetal Neonatal Med."},{"issue":"9","key":"666_CR8","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1007\/s00520-017-3690-z","volume":"25","author":"A Mafodda","year":"2017","unstructured":"Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Supp Care Cancer. 2017;25(9):2779\u201386.","journal-title":"Supp Care Cancer"},{"issue":"4","key":"666_CR9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3892\/mco.2015.555","volume":"3","author":"G Giordano","year":"2015","unstructured":"Giordano G, Mondello P, Tambaro R, Perrotta N, D\u2019amico F, D\u2019aveta A, et al. Biosimilar epoetin \u03b1 is as effective as originator epoetin-\u03b1 plus liposomal iron (Sideral\u00ae), vitamin B12 and folates in patients with refractory anemia: a retrospective real-life approach. Mol Clin Oncol. 2015;3(4):781\u20134.","journal-title":"Mol Clin Oncol."},{"issue":"4","key":"666_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/ndt\/gfu357","volume":"30","author":"A Pisani","year":"2014","unstructured":"Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2014;30(4):645\u201352.","journal-title":"Nephrol Dial Transplant"},{"key":"666_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.endinu.2017.10.007","volume":"65","author":"A Ciudin","year":"2018","unstructured":"Ciudin A, Sim\u00f3-Servat O, Balibrea JM, Vilallonga R, Hernandez C, Sim\u00f3 R, et al. Response to oral sucrosomial iron supplementation in patients undergoing bariatric surgery. The BARI-FER study. Endocrinol Diabetes Nutr. 2018;65:17\u201320.","journal-title":"Endocrinol Diabetes Nutr."},{"issue":"3","key":"666_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF03321480","volume":"7","author":"C Rubio-Terr\u00e9s","year":"2010","unstructured":"Rubio-Terr\u00e9s C, L\u00f3pez \u00c1F, Montero AF, Vega JM, Castelao AM, Gisbert JP, et al. An\u00e1lisis farmacoecon\u00f3mico del tratamiento de la deficiencia de hierro con hierro carboximaltosa (Ferinject\u00ae) en Espa\u00f1a. PharmacoEcon Span Res Articles. 2010;7(3):109\u201317.","journal-title":"PharmacoEcon Span Res Articles."},{"key":"666_CR13","unstructured":"Mart\u00edn JE. An\u00e1lisis coste-beneficio de la utilizaci\u00f3n de Ferinject. 2014."},{"key":"666_CR14","unstructured":"Egocheaga MI, Lobos JM, Guissasola FA, Alc\u00e1zar R, Orte L, Parra EG, et al. Documento de consenso sobre la enfermedad renal cr\u00f3nica. Sociedad Espa\u00f1ola de Nefrolog\u00eda (SEN). Sociedad Espa\u00f1ola de Medicina de Familia y Comunitaria (semFYC). Barcelona: semFYC Ediciones; 2007."},{"issue":"2","key":"666_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.nefro.2015.10.020","volume":"36","author":"EM Escobar","year":"2016","unstructured":"Escobar EM, de Enfermos Renales RE. Registro Espa\u00f1ol de Enfermos Renales. Informe 2013 y evoluci\u00f3n 2007\u20132013. Nefrolog\u00eda. 2016;36(2):97\u2013120.","journal-title":"Nefrolog\u00eda."},{"key":"666_CR16","unstructured":"Instituto Nacional de Estad\u00edstico (INE) Proyecciones de poblaci\u00f3n a corto plazo. 2011\u20132021. \n                    http:\/\/www.ine.es\/jaxi\/menu.do?type=pcaxis&path=%2Ft20%2Fp269%2F2011-2021&file=pcaxis&L=\n                    \n                  . Accessed 19 Dec 2017."},{"key":"666_CR17","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. BOT plus web. 2012. \n                    https:\/\/botplusweb.portalfarma.com\/\n                    \n                  . Accessed 12 Dec 2017."},{"key":"666_CR18","unstructured":"Orden 731\/2013, de 6 de septiembre, del Consejero de Sanidad, por la que se fijan los precios p\u00fablicos por la prestaci\u00f3n de los servicios y actividades de naturaleza sanitaria de la Red de Centros de la Comunidad de Madrid. \n                    http:\/\/www.madrid.org\/wleg\/servlet\/Servidor?opcion=VerHtml&nmnorma=8275&cdestado=P\n                    \n                  . Accessed Dec 2017."},{"key":"666_CR19","unstructured":"Llei 12\/2015, de 29 de desembre, de mesures fiscals, de gesti\u00f3 administrativa i financera, i d\u2019organitzaci\u00f3 de la Generalitat de la Comunitat Valenciana. Available at: \n                    www.dogv.gva.es\/datos\/2015\/12\/31\/pdf\/2015_10410.pdf\n                    \n                  . Accessed Dec 2017."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0666-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0666-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0666-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T23:07:51Z","timestamp":1561158471000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0666-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0666-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"22 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Josep Darb\u00e0 is employed by the University of Barcelona, and Meritxell Ascanio is an employee of BCN Health Economics & Outcomes Research S.L., an independent contract health economic organization that has received research funding from Zambon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was sponsored by Zambon.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}